galantamine has been researched along with Cardiovascular Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aden, LA; Diedrich, A; Ding, T; Kirabo, A; Milne, GL; Parsa, D; Pitzer, A; Shibao, CA; Yu, C | 1 |
| Kaushik, V; Mikobi, E; Raji, MA; Smith, ST | 1 |
| Bozoglu, E; Celik, T; Isik, AT; Kaptan, K | 1 |
| Kinnair, D; Machili, C; Prettyman, R; Van Diepen, E | 1 |
| Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G | 1 |
| Ezhov, IuS; Ganina, SS; Kovanev, VA | 1 |
1 review(s) available for galantamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Comorbidity; Donepezil; Galantamine; Polypharmacy; Rivastigmine | 2018 |
1 trial(s) available for galantamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Enhanced parasympathetic cholinergic activity with galantamine inhibited lipid-induced oxidative stress in obese African Americans.
Topics: Acetylcholinesterase; Adult; Black or African American; Cardiovascular Diseases; Cholinergic Agents; Cross-Over Studies; Double-Blind Method; Female; Galantamine; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Lipids; Middle Aged; Obesity; Oxidative Stress | 2022 |
5 other study(ies) available for galantamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of galantamine on platelet functions in healthy elderly people.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Cardiovascular Diseases; Female; Galantamine; Healthy Volunteers; Humans; Male; Platelet Aggregation | 2013 |
Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Multivariate Analysis; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2011 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic | 2004 |
Anti-Alzheimer drugs: life-threatening adverse effects.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; France; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines | 2007 |
[Comparative evaluation of the efficacy of non-depolarizing muscle relaxant antidotes in patients with cardiovascular diseases].
Topics: Anesthesia, General; Anesthetics; Cardiovascular Diseases; Galantamine; Humans; Neostigmine; Pantothenic Acid; Tubocurarine | 1971 |